Dong-A Progresses In Diabetes With Lat Am Deal, New Study
This article was originally published in PharmAsia News
Executive Summary
With the global diabetes treatment market expected to show continued growth, South Korea's Dong-A ST is making progress in the sector by signing an additional licensing out contract for its new drug and successfully completing a Phase II U.S. study with a potential diabetic neuropathy therapy.
You may also be interested in...
Dong-A Ties With NeuroBo For Diabetic Neuropathy, Alzheimer's
Dong-A makes notable progress in botanical drug programs, reaching deals for its diabetic neuropathic pain and Alzheimer's disease drug assets with Boston-based NeuroBo Pharmaceuticals.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.